dc.contributor.author | Hislop, Jennifer | |
dc.contributor.author | Mowatt, Graham | |
dc.contributor.author | Sharma, Pawana | |
dc.contributor.author | Fraser, Cynthia | |
dc.contributor.author | Elders, Andrew | |
dc.contributor.author | Jenkinson, David | |
dc.contributor.author | Vale, Luke | |
dc.contributor.author | Petty, Russell | |
dc.date.accessioned | 2012-06-08T11:00:00Z | |
dc.date.available | 2012-06-08T11:00:00Z | |
dc.date.issued | 2012-06 | |
dc.identifier | 13512938 | |
dc.identifier | 220ee7d8-35d9-4225-b8f3-1ba7e6dbe804 | |
dc.identifier | 84863877145 | |
dc.identifier.citation | Hislop , J , Mowatt , G , Sharma , P , Fraser , C , Elders , A , Jenkinson , D , Vale , L & Petty , R 2012 , ' Systematic Review of Escalated Imatinib Doses Compared with Sunitinib or Best Supportive Care, for the Treatment of People with Unresectable/Metastatic Gastrointestinal Stromal Tumours Whose Disease has Progressed on the Standard Imatinib Dose ' , Journal of Gastrointestinal Cancer , vol. 43 , no. 2 , pp. 168-176 . https://doi.org/10.1007/s12029-011-9325-6 | en |
dc.identifier.issn | 1941-6628 | |
dc.identifier.uri | http://hdl.handle.net/2164/2482 | |
dc.description | PMID: 21971958 [PubMed - indexed for MEDLINE] PMCID: PMC3348468 Free PMC Article This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited | en |
dc.format.extent | 9 | |
dc.format.extent | 218536 | |
dc.language.iso | eng | |
dc.relation.ispartof | Journal of Gastrointestinal Cancer | en |
dc.subject | SDG 3 - Good Health and Well-being | en |
dc.subject | GIST | en |
dc.subject | gastrointestinal stromal tumours | en |
dc.subject | unresectable | en |
dc.subject | metastatic | en |
dc.subject | cancer | en |
dc.subject | imatinib | en |
dc.subject | sunitinib | en |
dc.subject | antineoplastic agents | en |
dc.subject | benzamides | en |
dc.subject | clinical trials as topic | en |
dc.subject | disease progression | en |
dc.subject | dose-response relationship | en |
dc.subject | gastrointestinal stromal tumors | en |
dc.subject | humans | en |
dc.subject | indoles | en |
dc.subject | piperazines | en |
dc.subject | pyrimidines | en |
dc.subject | pyrroles | en |
dc.subject | treatmemnt outcome | en |
dc.subject | RC0254 Neoplasms. Tumors. Oncology (including Cancer) | en |
dc.subject.lcc | RC0254 | en |
dc.title | Systematic Review of Escalated Imatinib Doses Compared with Sunitinib or Best Supportive Care, for the Treatment of People with Unresectable/Metastatic Gastrointestinal Stromal Tumours Whose Disease has Progressed on the Standard Imatinib Dose | en |
dc.type | Journal article | en |
dc.contributor.institution | University of Aberdeen.Other Applied Health Sciences | en |
dc.contributor.institution | University of Aberdeen.Health Services Research Unit | en |
dc.contributor.institution | University of Aberdeen.Applied Medicine | en |
dc.description.status | Peer reviewed | en |
dc.identifier.doi | 10.1007/s12029-011-9325-6 | |